Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Searle's Cytotec (misoprostol)

Executive Summary

Abortifacient side effect was subject of Nov. 3 meeting between FDA Commissioner Young and representatives of the National Right to Life Committee. A Sept. 15 Gastrointestinal Drugs Advisory Committee recommended approval for Cytotec for the prevention of stomach ulcers in patients taking nonsteroidal anti-inflammatory arthritis drugs. At the meeting, the panel rejected Searle's proposal that Cytotec be contraindicated for women of childbearing age ("The Pink Sheet" Sept. 19, p. 3). The Right to Lifers maintain that a prominent warning label may encourage use of Cytotec as an abortifacient. Young has scheduled a December staff meeting to review the group's concerns....
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel